GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (STU:TPM0) » Definitions » Cash Conversion Cycle

Tonix Pharmaceuticals Holding (STU:TPM0) Cash Conversion Cycle : 440.74 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Tonix Pharmaceuticals Holding Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Tonix Pharmaceuticals Holding's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.
Tonix Pharmaceuticals Holding's Days Inventory for the three months ended in Mar. 2024 was 727.13.
Tonix Pharmaceuticals Holding's Days Payable for the three months ended in Mar. 2024 was 286.39.
Therefore, Tonix Pharmaceuticals Holding's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 440.74.


Tonix Pharmaceuticals Holding Cash Conversion Cycle Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Cash Conversion Cycle Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 623.95

Tonix Pharmaceuticals Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 255.82 347.10 440.74

Competitive Comparison of Tonix Pharmaceuticals Holding's Cash Conversion Cycle

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tonix Pharmaceuticals Holding's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Cash Conversion Cycle falls into.



Tonix Pharmaceuticals Holding Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Tonix Pharmaceuticals Holding's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+1089.29-465.34
=623.95

Tonix Pharmaceuticals Holding's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+727.13-286.39
=440.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tonix Pharmaceuticals Holding  (STU:TPM0) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Tonix Pharmaceuticals Holding Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Tonix Pharmaceuticals Holding (STU:TPM0) Business Description

Traded in Other Exchanges
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Tonix Pharmaceuticals Holding (STU:TPM0) Headlines

No Headlines